Document Detail

Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel.
MedLine Citation:
PMID:  11595125     Owner:  NLM     Status:  MEDLINE    
We evaluated the sequence dependency of antitumor efficacy and toxicity in combination therapy of nedaplatin (NDP) with paclitaxel (TXL) against Lewis lung carcinoma. The sequential administration of NDP prior to TXL (NT therapy) resulted in severe body weight loss followed by frequent toxic death of mice. In contrast, the sequential dosing of TXL prior to NDP (TN therapy) resulted in synergistically enhanced inhibition of tumor growth with less toxicity compared with the NT therapy. Comparing the antitumor activity of NDP plus TXL with that of cisplatin (CDDP) plus TXL or carboplatin (CBDCA) plus TXL, the combination effect of NDP plus TXL was significantly higher than that of CDDP plus TXL or CBDCA plus TXL. These results indicate that the TN therapy may have significant potential in clinical use.
H Yamada; N Uchida; R Maekawa; T Yoshioka
Related Documents :
11479865 - Continuous intrapulmonary distension with perfluorocarbon accelerates lung growth in in...
3382485 - Tracheal plugs in oligohydramnios.
12065185 - Perinatal corticosteroids and the developing lung.
17050555 - Alterations of exhaled nitric oxide in pre-term infants with chronic lung disease.
25151365 - Genetic diversity among candida albicans isolates associated with vertical transmission...
14758955 - Nonsurgical treatment of a c6-7 unilateral locked facet joint in an infant. case report.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer letters     Volume:  172     ISSN:  0304-3835     ISO Abbreviation:  Cancer Lett.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-10-11     Completed Date:  2001-11-01     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  7600053     Medline TA:  Cancer Lett     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  17-25     Citation Subset:  IM    
Discovery Research Labs, Shionogi Research Laboratories, Shionogi & Co., Ltd, 12-4 Sagisu, 5-chome, Fukusima-ku, Osaka 552-0002, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents, Phytogenic / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Body Weight / drug effects
Carboplatin / administration & dosage
Carcinoma, Lewis Lung / drug therapy
Cisplatin / administration & dosage
Liver / drug effects
Lung Neoplasms / drug therapy
Mice, Inbred C57BL
Organoplatinum Compounds / administration & dosage*
Paclitaxel / administration & dosage*
Time Factors
Reg. No./Substance:
0/Antineoplastic Agents; 0/Antineoplastic Agents, Phytogenic; 0/Organoplatinum Compounds; 15663-27-1/Cisplatin; 33069-62-4/Paclitaxel; 41575-94-4/Carboplatin; 95734-82-0/nedaplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Exogenous expression of p21(WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cis...
Next Document:  Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic ad...